EUROPEAN JOURNAL OF ENDOCRINOLOGY欧洲内分泌学杂志
EUROPEAN JOURNAL OF ENDOCRINOLOGY(英文缩写 EUR J ENDOCRINOL),ISSN 0804-4643,eISSN 1479-683X,中文译名:欧洲内分泌学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 6.558 | Q1 |
| 2022 | 5.800 | Q1 |
| 2023 | 5.300 | Q1 |
| 2024 | 5.200 | Q1 |
| 2025 | 6.700 | Q1 |
EUROPEAN JOURNAL OF ENDOCRINOLOGY 最新收录文献
-
1. Off-label palopegteriparatide for severe pediatric postsurgical hypocalcemia.
PMID:日期:2026-09-25Hypoparathyroidism is the most common complication after total thyroidectomy and may be particularly severe in pediatric Graves' disease. We report the case of a 14-year-old boy with Graves' disease who developed profound postoperative hypocalcemia after total thyroidectomy, with serum calcium 5.9 mg/dL, ionized calcium 0.83 mmol/L, and undetectable parathyroid hormone. Despite intravenous and high-dose oral calcium plus calcitriol, biochemical control remained poor, with persistent hypocalcemia, hyperphosphatemia, and ongoing treatment requirements after 16 days. Off-label subcutaneous palopegteriparatide, a long-acting PTH(1-34) prodrug, was started after multidisciplinary assessment and informed family consent. Serum calcium improved within 48 h, intravenous calcium was stopped after 5 days, and calcitriol, sevelamer, and calcium acetate were discontinued within 11 days. Treatment was well tolerated. This case suggests that early PTH replacement may be a useful rescue strategy in selected children with severe refractory post-thyroidectomy hypocalcemia.
-
2. Environmental pollution is associated with poorer survival in patients with adrenocortical carcinoma: findings from a national cohort study in Italy.
PMID:日期:2026-09-25The impact of environmental pollution on adrenocortical carcinoma (ACC) remains largely unexplored. Although a few studies have assessed the incidence of ACC in polluted areas, no data are available on clinical outcomes. We carried out a retrospective multicentre cohort study in adult patients with ACC diagnosed in 12 referral centres in Italy (1990-2018). We stratified patients for (i) residence in sites officially classified as contaminated (NPCSs: National Priority Contaminated Sites) or in non-contaminated areas; (ii) urbanization, as a contextual proxy for environmental exposure. Outcomes were recurrence-free survival (RFS) and overall survival (OS). Among 336 patients, 250 had localized disease (stage I-III) and 86 metastatic disease (stage IV). Subgroups among patients with stage IV ACC were too small for a meaningful analysis. Among patients with localized ACC, 26 (10.4%) living in NPCSs had significantly shorter median RFS (13 vs 43 months; p=0.011) and OS (67 vs 142 months; p=0.016) compared to the 224 patients living in non-contaminated areas. At multivariable analysis, residence in NPCSs was independently associated with both recurrence (HR 1.89, 95% CI 1.13-3.16, p=0.016) and death (HR 2.44, 95% CI 1.39-4.28, p=0.002). No significant association was found between the level of urbanization and survival. This study provides the first evidence that environmental pollution is associated with worse clinical outcomes in patients with ACC. By linking contaminated-area residence with prognosis, these findings raise the possibility that environmental exposures may contribute to the disease behaviour, highlighting a new direction for integrated epidemiological and biological research.
-
3. Transition to once-weekly growth hormone in paediatric isolated growth hormone deficiency: A real-world experience.
PMID:日期:2026-09-24To evaluate real-world auxological and biochemical outcomes in children and adolescents with isolated growth hormone deficiency (GHD) who transitioned from daily recombinant human growth hormone to once-weekly somatrogon. Single-centre retrospective observational study. Seventy-three paediatric patients with isolated GHD (52 boys) transitioned to weekly somatrogon at a mean age of 12.56 ± 2.87 years. At the time of data collection, all 73 patients had completed 6 months of follow-up, while 58 and 27 patients had completed 12 and 18 months, respectively. Primary outcomes were changes in height standard deviation score (SDS) and height velocity SDS. Secondary outcomes included body mass index (BMI) SDS, weight SDS, and serum insulin-like growth factor-1 (IGF-1) SDS. Assessments were performed 6 months prior to transition and at 6, 12, and 18 months after initiation of long-acting growth hormone therapy. Height SDS increased, while height velocity SDS remained positive throughout follow-up. BMI SDS increased significantly during the first year after transition but stabilized by 18 months. Serum IGF-1 SDS showed an early increase at 6 months and subsequently declined. Transition from daily growth hormone to once-weekly somatrogon maintained effective growth outcomes in paediatric patients with isolated GHD. These findings support the effectiveness of weekly therapy in routine clinical practice. Further long-term studies are needed to better characterize metabolic effects and inform individualized treatment strategies.
-
4. Pituitary adenomas in older patients - approaches, challenges and future directions.
PMID:日期:2026-09-23Several pituitary adenomas are diagnosed at an old age. Over the decades, the increase in life expectancy has led to fundamental changes in the age structure of the society. As a result of this, the number of elderly patients newly diagnosed or living with a pituitary adenoma is increasing. Clinical phenotypes in this group often differ from that encountered in younger patients, and ageing can have a negative impact on pituitary adenoma-related comorbidities. Timely diagnosis may be influenced by factors including confusion with physical changes occurring during normal ageing, presence of visual abnormalities mimicking those caused by pituitary adenomas and age-related alterations in pituitary function. In this review, we present data on various types of pituitary adenomas diagnosed in the elderly from the published literature of the last 20 years, discuss differences with younger patients and highlight diagnostic and therapeutic challenges in this field. Overall, essential priority is to offer a patient-tailored management strategy which will be effective, safe, pragmatic, enhancing optimal age-adjusted quality of life and considering patient wishes and frailty. Directing the management to centers of excellence with proven and established surgical/endocrine expertise combined with wider multi-disciplinary input will serve this priority.
-
5. Multimodal Imaging for Adrenal Tumor Characterization: Clinical Impact of the 2023 European Guidelines - A Single-Center Retrospective Study.
PMID:日期:2026-09-21Adrenal lesions are becoming increasingly common with the advent of abdominal imaging. Although mostly benign and nonfunctional, some cases may be malignant or secretory and justify adrenalectomy. The 2023 European guidelines propose a more conservative approach (focused on simple radiological criteria) to limit unnecessary surgery. However, the impact of this strategy on the management of malignant lesions remains to be assessed. We conducted a single-center retrospective study including all patients who underwent adrenalectomy between 2017 and 2024. The aim was to investigate the potential impact of the new iconographic criteria of the 2023 European recommendations. Patients aged over 18 years with at least one preoperative imaging examination and a histopathology report were included. Among 259 patients, 75% had benign lesions, and 25% had malignant lesions. Based on the 2016 guidelines, 71% of the patients would have undergone surgery, whereas 31% would have undergone surgery according to the 2023 criteria. With respect to malignant lesions, 98% of the patients would have received surgery according to the 2016 criteria, whereas 60% would have received surgery according to the 2023 criteria. The inclusion of hypersecretion increased this rate to 93%, and the addition of complementary imaging ensured the detection of all malignant cases. The 2023 guidelines may substantially reduce unnecessary adrenalectomies for benign lesions. The risk of missing malignant tumors remains low when hormonal evaluation and multimodal imaging (such as MRI and FDG-PET) are used, particularly in indeterminate cases.
-
6. Dietary Interventions and Vitamin D3 Replacement in Pituitary Tumors: a Systematic Review.
PMID:日期:2026-09-20Pituitary neuroendocrine tumors (PitNETs) cause hormonal imbalances that impair metabolic health and quality of life (QoL). Dietary interventions may mitigate these comorbidities. This review evaluated the effectiveness of dietary strategies in improving disease-related metabolic, and bone outcomes in patients with PitNETs. Systematic review of interventional and observational studies on dietary interventions in acromegaly, Cushing's disease, prolactinomas, and hypopituitarism. A systematic search was performed on January 20th, 2026. Eligible studies assessed dietary interventions targeting metabolic or bone-related outcomes. Risk of bias was evaluated using ROBINS-I and the Newcastle-Ottawa Scale. Extracted outcomes included dietary intake, body composition, metabolic parameters, biochemical control, and bone health. Of 2,256 screened records, eight studies (355 participants) met the inclusion criteria, including five interventional and three observational studies. In acromegaly, an isocaloric very low-carbohydrate ketogenic diet (VLCKD) reduced IGF-I levels. In Cushing's disease, VLCKD and energy-restricted diets (ERD) improved BMI and metabolic parameters. In prolactinoma, ERD combined with increased physical activity improved weight and biochemical control. In hypopituitarism, ERD with increased physical activity and sibutramine improved body composition and metabolic outcomes. Vitamin D replacement reduced vertebral fracture risk in acromegaly and improved insulin sensitivity and lipid levels in Cushing's disease. Evidence on dietary strategies for PitNET management is limited. Low-carbohydrate and energy-restricted diets may improve adverse metabolic comorbidities, while vitamin D3 replacement shows potential benefits for insulin sensitivity in Cushing's disease and fracture risk in acromegaly. Larger randomized trials are needed to confirm effects on disease control, comorbidities, and QoL.
-
7. Bone marrow responses to GLP-1 and GIP infusion under hyperglycaemic conditions.
PMID:日期:2026-09-19Food intake stimulates secretion of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which acutely suppress systemic markers of bone resorption in humans. Whether incretins exert parallel effects on bone turnover within the bone marrow (BM) microenvironment during hyperglycaemia is unknown. We investigated the acute effects of GLP-1, GIP, and their combination on bone turnover in BM under hyperglycaemic conditions, alongside BM metabolomics and stromal cell characteristics. Crossover study in healthy men. Twelve men completed three study days with two-hour intravenous infusions of GLP-1, GIP, or combined GLP-1+GIP during a hyperglycaemic clamp targeting postprandial plasma glucose. Bone resorption (C-terminal telopeptide of type I collagen, CTX) and formation (procollagen type I N-terminal propeptide, P1NP) markers were measured in peripheral plasma during infusions and in BM plasma before and after infusions. Untargeted metabolomic profiling by liquid chromatography-mass spectrometry was performed on BM plasma, and BM stromal cells (BMSCs) were assessed ex vivo for clonogenic capacity and osteogenic and adipogenic differentiation. All infusions suppressed BM plasma CTX to a similar extent. P1NP increased transiently in peripheral plasma during GIP and GLP-1+GIP infusions and was elevated in BM plasma after GIP infusion. Metabolomics revealed changes consistent with altered glucose and insulin levels, without a bone-specific signature. BMSC differentiation was unchanged, although clonogenic capacity was reduced after GLP-1+GIP infusion. Under hyperglycaemic conditions, both incretins acutely suppressed bone resorption in healthy men without detectable bone-specific metabolic signatures. GIP was additionally associated with increased BM P1NP at 2 hours, in contrast to only a short-lived rise in peripheral plasma, suggesting a possible transient uncoupling of bone turnover.
-
8. Cardiovascular Morbidity in Acromegaly during a Long-term Follow-Up - a Nationwide Cohort Study.
PMID:日期:2026-09-18Acromegaly has been associated with increased cardiovascular morbidity, but it is unclear to what extent this holds true in contemporary acromegaly cohorts and when the cardiovascular diseases (CVDs) evolve in relation to the time of diagnosis. Retrospective cohort study. Cardiovascular morbidity was studied in the Finnish acromegaly cohort (n = 565) and 5629 controls using Kaplan-Meier analysis from 10 years before the diagnosis of acromegaly and continuing up to >30 years after the diagnosis. Hazard ratios for CVD-related hospital visits were calculated with Cox regression analyses in the post-diagnosis period. The effects of received treatments, hypopituitarism, and biochemical control of acromegaly were studied with multivariable analyses among the patients. Cardiovascular morbidity increased years before the diagnosis of acromegaly and remained elevated compared to controls [HR 1.59 (95% CI 1.42-1.78)] throughout the follow-up (median 17.2 years, interquartile range 8.7-26.5 years). The highest increase was observed in diseases of pulmonary arteries [HR 2.74 (1.87-4.02)], valvular diseases and cardiomyopathies [HR 2.68 (2.09-3.44)] and hypertension [HR 2.11 (1.85-2.42)]. Radiotherapy, hypopituitarism, and post-treatment IGF-1 above or below the reference range were associated with increased cardiovascular morbidity. Even patients who achieved biochemical remission and normal pituitary function after surgery suffered from increased morbidity compared to controls. Patients with acromegaly are still characterised by increased morbidity across a wide range of CVDs. Cardiovascular morbidity is already present before diagnosis and persists despite acromegaly-specific therapy. This underlines the importance of early diagnostics and CVD prevention for these patients.
-
9. Genetic testing and reporting: What the endocrinologists should know and can expect (Joint position paper of the ENDO-ERN).
PMID:日期:2026-09-16Over the last decade, next generation sequencing (NGS) has become an essential tool for diagnostic DNA testing in human genetics. To improve the understanding of available genetic testing strategies and to facilitate the request of genetic testing in daily endocrine practice, clinical and laboratory experts in the field have summarized the major issues which should be known and considered. In this joint position paper of the ENDO-ERN, the roles and responsibilities of the health care professionals involved in the diagnostic workflow are described, and the major issues concerning genetic testing workflows are overviewed. These issues encompass all relevant steps, including test request and pre-analytical procedures, laboratory and data processing workflows, quality assurance, and reporting. As NGS procedures result in an increasing number of variants of unknown significance and incidental findings, these aspects are addressed as well. Accompanied by illustrations of the genetic diagnostic workflow and of concise reports for a fast orientation about the major aspects of genetic testing, this joint paper should support the health care professionals during a request for genetic testing.
-
10. Distinguishing hyperparathyroidism from insulin-like growth factor I-driven calcium-phosphate metabolism changes in acromegaly.
PMID:日期:2026-08-28Acromegaly is frequently associated with disturbances in calcium-phosphate metabolism, including mild hypercalcemia. Hypercalcemia may also reflect primary hyperparathyroidism (PHPT), which can occur with or without variants in MEN1 or the related genes. Distinguishing PHPT from insulin-like growth factor I (IGF-I)-related alterations in mineral metabolism remains challenging. We aimed to assess the prevalence and characteristics of PHPT in patients with acromegaly and explore biochemical approaches for identifying parathyroid autonomy. We conducted a retrospective study at 2 French university hospitals, including adults with acromegaly who had at least 1 serum calcium measurement obtained during uncontrolled disease. Three diagnostic approaches based on serum calcium and phosphate levels were evaluated: a threshold-based decision rule, logistic regression, and a support vector machine model. Among 393 patients (54% women; median age 43 years [interquatile range 33-55]), 23 (5.9%) had concomitant PHPT. In isolated acromegaly, hyperphosphatemia occurred in 37.3% and mild hypercalcemia in 3.2% of patients; both resolved after acromegaly treatment. Patients with PHPT had persistent mild hypercalcemia (median calcium 2.72 mmol/L [interquatile range 2.66-2.86]), elevated PTH, and low-to-normal phosphate levels, these abnormalities resolved after parathyroid surgery in the 10 operated patients. No pathogenic variants were identified in the tested genes. A threshold-based rule combining calcium >2.60 mmol/L and phosphate <1.46 mmol/L showed excellent diagnostic performance for identifying parathyroid autonomy, with bootstrap 0.632+ corrected sensitivity and specificity of 0.940 and 0.993, respectively, and was preferred because of its simplicity. PHPT may be more frequent in acromegaly than in the general population. In patients with acromegaly and hypercalcemia, a nonelevated phosphate level strongly suggests concomitant PHPT, whereas an elevated phosphate level favors IGF-I-related mineral disturbances.